No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $81 Price Target
Morgan Stanley Maintains Equal-Weight on Arvinas, Lowers Price Target to $12
Arvinas Analyst Ratings
Arvinas Is Maintained at Buy by Guggenheim